Navigation Links
Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Date:3/13/2008

- Dendreon to Hold Conference Call Today, March 13, 2008 at 11:00 AM ET -

SEATTLE, March 13 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2007. Revenues for the year ended December 31, 2007 were $743,000 compared to $273,000 for the year ended December 31, 2006. Revenues for the fourth quarter of 2007 were $28,000, compared to $86,000 for the same period in 2006.

The net loss for the year ended December 31, 2007 was $99.3 million, or $1.20 per share, compared to $91.6 million, or $1.27 per share for the year ended December 31, 2006. Net loss in the fourth quarter of 2007 was $27.0 million or $0.32 per share, compared to a net loss of $21.5 million, or $0.28 per share, for the same period in 2006. Dendreon's total operating expenses for the year ended December 31, 2007 were $102.4 million compared to $97.6 million in 2006. Net cash used in operating activities in 2007 was $82.6 million compared to $80.8 million in 2006.

As of December 31, 2007, Dendreon had approximately $120.6 million in cash, cash equivalents, and short-term and long-term investments compared to $121.3 million as of December 31, 2006.

Recent Highlights:

-- The FDA agreed to amend the IMPACT (IMmunotherapy for Prostate

AdenoCarcinoma Treatment) Special Protocol Assessment (SPA),

accelerating the expected timeline for final results from the study by

approximately one year while maintaining comparable power to the

previous SPA. In addition, the FDA reconfirmed that either a positive

interim or final analysis of survival would support licensure and

enable Dendreon to amend the company's biologic
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014  Ardelyx, Inc. (NASDAQ: ARDX ... gastrointestinal and metabolic diseases, today announced that it ... Thursday, November 6, 2014. Following the announcement, the ... call and webcast at 4:30pm ET to review ... update. The live webcast can be ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 On ... Cellular Medicine Showcase in Chicago, leading applied stem ... Surgeon, Dr. Wade McKenna presented talks on New ... Orthopedic Surgical Applications For Stem Cells. , Dr. ... membrane and the properties of AlphaGEMS that include: ...
(Date:10/30/2014)... James Sherley says he has been working ... cell technology since his days as a principal investigator at ... late 1990’s. Sherley founded the ASCTC as a new ... the intellectual property developed in Sherley’s research over the years ... of Technology (MIT), and more recently as a senior scientist ...
(Date:10/30/2014)... Erlanger, Kentucky (PRWEB) October 30, 2014 Avure ... of the 525L, the newest member of its fleet of ... to be reaching an anniversary as we return to PackExpo ... a year ago in Las Vegas,” said Jeff Williams, CEO ... extremely well, and we’re pleased to be meeting the challenges ...
Breaking Biology Technology:Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... Directors, SAN DIEGO, Jan. 31 Sonexa ... the,treatment of Alzheimer,s disease, announced today that it ... of financing. The financing was led by Domain,Associates, ... included AgeChem Venture Fund, and MC Life Science ...
... across North ... America, OTTAWA, ... performance and talent management software,today announced that strong fourth quarter results have ... the healthcare,market. To help boost its growth, Halogen secured a number of ...
... Jan. 31 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group ... volume of bio-fertilizer products during the fourth,quarter ... Ltd. ("Kiwa,Shandong"), the Company,s wholly-owned subsidiary operating ... bio-fertilizer products during,the last quarter of 2007 ...
Cached Biology Technology:Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 2Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 3Halogen Advances its Lead in Providing Employee Performance and Talent Management Solutions for the Healthcare Market 2Kiwa Bio-Tech Ships 114 Tons of Bio-Fertilizer in Fourth Quarter of 2007 2
(Date:10/31/2014)... steps involved in programmed cell death, offering new targets ... neurodegenerative diseases. , The research teams from the ... the three-dimensional structure of a key cell death protein ... it causes cell death. Their studies were published in ... Proceedings of the National Academy of Sciences . ...
(Date:10/31/2014)...  HITLAB SM , a healthcare innovation and ... HITLAB Innovators Summit SM on December 1, ... partner with the Clinton Foundation,s Health Matters Initiative, ... Business School Alumni Club of New ... Operations Research, bringing together leaders in healthcare and ...
(Date:10/30/2014)... EAST LANSING, Mich. – When most animals begin life, ... tail or a vital organ. However, mammals, including humans, ... make a different first choice – to become the ... , It,s during this critical first step that research ... results, published in the current issue of ...
Breaking Biology News(10 mins):A matter of life and death: Cell death proteins key to fighting disease 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3Identifying the source of stem cells 2
... A newly published report reveals that children with ... gender a determining factor in their development. Findings showed ... more hyperactivity/inattention problems and issues regarding peer relationships. Details ... online in Epilepsia , a journal published by ...
... scanner aboard the international space station has been taking new ... it was launched, providing scientists with a new set of ... spills to plankton blooms. The images and other data ... an online clearinghouse coordinated by Oregon State University. Additional ...
... 24, 2011 Cytel , a leading provider ... with oncology-focused CRO Medelis , the opening of ... Development With Adaptive Studies ". Over 50% ... a distressing reality, especially for oncologists and developers of ...
Cached Biology News:Higher prevalence of psychiatric symptoms found in children with epilepsy 2Higher prevalence of psychiatric symptoms found in children with epilepsy 3Data streaming in from Space Station to OSU lab 2Data streaming in from Space Station to OSU lab 3Cytel and Medelis Present an Educational Webinar April 7: Transforming Oncology Development with Adaptive Studies 2
... The iCycler thermal cycler with 384-well reaction ... (PCR) applications. It is equipped with an ... and features algorithm temperature monitoring and control ... small sample volumes. It includes the iCycler ...
... DNA Engine instrument is the cycler ... Unprecedented thermal uniformity and swappable blocks ... This rugged machine is ... a platform for new features and ...
... The Gene Pulser Xcell microbial ... Hz, is used for electroporation of ... includes the main unit, PC module ... chamber, 10 sterile cuvettes (5 each ...
... Epithelial and endothelial cells-directed transfection ... RGD peptide-conjugated polyethylenimine which allows ... epithelial and endothelial cells. Integrins ... cell-cell and cell-matrix adhesion processes. ...
Biology Products: